COX-2-IN-7

COX-2-IN-7

• UNSPSC Description: COX-2-IN-7 (compound 4a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 6.585 uM. COX-2-IN-7 has higher COX-2 selectivity than Celecoxib. COX-2-IN-7 shows good in vivo anti-inflammatory and low ulcerogenic activity[1].
• Target Antigen: COX
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/cox-2-in-7.html
• Solubility: 10 mM in DMSO
• Smiles: CS(=O)(C1=CC=C(C=C1)N2N=C(N=C2C3=CC=CC=C3)S)=O
• Molecular Weight: 331.41
• References & Citations: [1]Abdellatif KRA, et al. Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on celecoxib scaffold supported with in vivo anti-inflammatory activity, ulcerogenic liability, ADME profiling and docking study [published online ahead of print, 2022 Jan 19]. Bioorg Chem. 2022;120:105627.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported